Pulmonary Arterial Hypertension (PAH): Market Assessment, Epidemiology & Market Forecast-2028
CmaxInsight’s “Pulmonary Arterial Hypertension (PAH): Market Assessment, Epidemiology & Market Forecast-2028” report provides an overview of the disease and market size of Pulmonary Arterial Hypertension (PAH) for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers epidemiology of Pulmonary Arterial Hypertension (PAH) from 2018 to 2028 segmented by seven major markets market along with market drivers, market barriers and unmet medical needs of this indication.
Research Scope
Pulmonary Arterial Hypertension (PAH) Overview and Treatment Landscape
The report provides comprehensive information of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the United States, Europe, and Japan are also covered.
Pulmonary Arterial Hypertension (PAH) Epidemiology
This section of the report provides the country-specific information of historical and current patient pool and offers forecasted value for prevalent/ incident cases, along with diagnosed and treatable patient pool.
Pulmonary Arterial Hypertension (PAH) Marketed and Emerging Drug Landscape
A snapshot on the marketed and pipeline emerging drugs, along with comprehensive insight on emerging treatments based on their safety & efficacy results, mechanism of action, route of administration, therapeutic potential, regulatory success, launch dates, and other factors.
This section also covers latest news which includes agreements and collaborations, approvals, patent details and other major breakthroughs.
Pulmonary Arterial Hypertension (PAH) Market Size and Segmentation
This segment of the report focuses on key question: “What is the size of the total & addressable market for Pulmonary Arterial Hypertension (PAH)”? This key question will help to answer whether the market is big enough to be interested in your business. Relevant and detailed patient segmentations are provided for each Indication, enabling to evaluate the commercial potential of the market.
Pulmonary Arterial Hypertension (PAH) Market Trends and Opportunities
Identify market trends and the opportunities by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Pulmonary Arterial Hypertension (PAH) Unmet Needs
Discover the significant current and future unmet needs for the Pulmonary Arterial Hypertension (PAH). Market requirements vary with different countries and geographies.
Methodologies
Our experts synthesize information from proprietary databases, syndicated reports, primary research and secondary data, such as company reports, press releases, published peer-reviewed journal articles, disease registries, and general news media to provide a complete picture of your market. Our approach ensures that every data point and inference goes through multiple validations while leveraging a variety of sources to formulate market and opportunity size.
Key Coverage and Benefits:
Research Scope
Pulmonary Arterial Hypertension (PAH) Overview and Treatment Landscape
The report provides comprehensive information of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the United States, Europe, and Japan are also covered.
Pulmonary Arterial Hypertension (PAH) Epidemiology
This section of the report provides the country-specific information of historical and current patient pool and offers forecasted value for prevalent/ incident cases, along with diagnosed and treatable patient pool.
Pulmonary Arterial Hypertension (PAH) Marketed and Emerging Drug Landscape
A snapshot on the marketed and pipeline emerging drugs, along with comprehensive insight on emerging treatments based on their safety & efficacy results, mechanism of action, route of administration, therapeutic potential, regulatory success, launch dates, and other factors.
This section also covers latest news which includes agreements and collaborations, approvals, patent details and other major breakthroughs.
Pulmonary Arterial Hypertension (PAH) Market Size and Segmentation
This segment of the report focuses on key question: “What is the size of the total & addressable market for Pulmonary Arterial Hypertension (PAH)”? This key question will help to answer whether the market is big enough to be interested in your business. Relevant and detailed patient segmentations are provided for each Indication, enabling to evaluate the commercial potential of the market.
Pulmonary Arterial Hypertension (PAH) Market Trends and Opportunities
Identify market trends and the opportunities by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
Pulmonary Arterial Hypertension (PAH) Unmet Needs
Discover the significant current and future unmet needs for the Pulmonary Arterial Hypertension (PAH). Market requirements vary with different countries and geographies.
Methodologies
Our experts synthesize information from proprietary databases, syndicated reports, primary research and secondary data, such as company reports, press releases, published peer-reviewed journal articles, disease registries, and general news media to provide a complete picture of your market. Our approach ensures that every data point and inference goes through multiple validations while leveraging a variety of sources to formulate market and opportunity size.
Key Coverage and Benefits:
- The report will help in developing business strategies by understanding the trends shaping and driving the global Pulmonary Arterial Hypertension (PAH) market.
- The report provides detailed historical and forecasted epidemiological data of Pulmonary Arterial Hypertension (PAH) in the 7MM from 2018-2028.
- Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension (PAH) in US, Europe and Japan.
- To understand the future market competition in the global Pulmonary Arterial Hypertension (PAH) and insightful review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
1. REPORT INTRODUCTION
2. PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET OVERVIEW AT GLANCE
3. DISEASE BACKGROUND AND OVERVIEW: PULMONARY ARTERIAL HYPERTENSION (PAH)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. PULMONARY ARTERIAL HYPERTENSION (PAH) EPIDEMIOLOGY
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. EPIDEMIOLOGY OF PULMONARY ARTERIAL HYPERTENSION (PAH) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.1.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.1.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.1.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.1.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.2.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.2.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.2.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.2.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.3.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.3.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.3.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.3.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.4.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.4.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.4.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.4.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.5.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.5.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.5.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.5.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.6.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.6.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.6.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.6.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.7.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.7.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.7.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.7.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
6. UNMET NEEDS
7. MARKETED DRUGS
7.1. Drug
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. EMERGING DRUGS
8.1. Drug
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. COUNTRY SPECIFIC MARKET ANALYSIS
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. MARKET DRIVERS
11. MARKET BARRIERS
12. MARKET OPPORTUNITIES
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
2. PULMONARY ARTERIAL HYPERTENSION (PAH) MARKET OVERVIEW AT GLANCE
3. DISEASE BACKGROUND AND OVERVIEW: PULMONARY ARTERIAL HYPERTENSION (PAH)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnostic Landscape
3.6.1. Diagnostic Practices
3.6.2. Diagnostic Criteria
3.6.3. Diagnostic Recommendations
3.7. Treatment Landscape
3.7.1. Current Treatment Practices
3.7.2. Treatment Algorithm
3.7.3. Treatment Recommendations
4. PULMONARY ARTERIAL HYPERTENSION (PAH) EPIDEMIOLOGY
4.1. Key Findings
4.2. Assumptions & Rationale
4.3. 7MM Epidemiology
5. EPIDEMIOLOGY OF PULMONARY ARTERIAL HYPERTENSION (PAH) BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.1.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.1.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.1.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.1.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.2. Germany
5.2.1. Assumptions and Rationale
5.2.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.2.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.2.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.2.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.2.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.3. France
5.3.1. Assumptions and Rationale
5.3.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.3.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.3.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.3.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.3.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.4. United Kingdom
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.4.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.4.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.4.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.4.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.5. Spain
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.5.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.5.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.5.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.5.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.6.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.6.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.6.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.6.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
5.7. Japan
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of Pulmonary Arterial Hypertension (PAH)
5.7.3. Sub-Type Specific cases of Pulmonary Arterial Hypertension (PAH)*
5.7.4. Sex- Specific Cases of Pulmonary Arterial Hypertension (PAH)*
5.7.5. Diagnosed Cases of Pulmonary Arterial Hypertension (PAH)
5.7.6. Treatable Cases of Pulmonary Arterial Hypertension (PAH)
6. UNMET NEEDS
7. MARKETED DRUGS
7.1. Drug
7.1.1. Product Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Safety and Efficacy
7.1.5 Side-Effects
7.1.6. Product Profile
7.1.7. Sales
7.1.8. Patent Data
8. EMERGING DRUGS
8.1. Drug
8.1.1. Product Description
8.1.2. Clinical Trial Information and Results
8.1.3. Product Development Activity
8.1.4. Regulatory Milestones
8.1.5. Product Profile
8.1.6. Expected Launch Date
9. COUNTRY SPECIFIC MARKET ANALYSIS
9.1. 7 Major Market Analysis
9.1.1. 7 Major Market Size
9.1.2. Therapy Wise Market Size
9.2. United States Market Analysis
9.2.1. United States Market Size
9.2.2. Therapy Wise Market Size
9.3. Germany Market Analysis
9.3.1. Germany Market Size
9.3.2. Therapy Wise Market Size
9.4. France Market Analysis
9.4.1. France Market Size
9.4.2. Therapy Wise Market Size
9.5. United Kingdom Market Analysis
9.5.1. United Kingdom Market Size
9.5.2. Therapy Wise Market Size
9.6. Spain Market Analysis
9.6.1. Spain Market Size
9.6.2. Therapy Wise Market Size
9.7. Italy Market Analysis
9.7.1. Italy Market Size
9.7.2. Therapy Wise Market Size
9.8. Japan Market Analysis
9.8.1. Japan Market Size
9.8.2. Therapy Wise Market Size
10. MARKET DRIVERS
11. MARKET BARRIERS
12. MARKET OPPORTUNITIES
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 4: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Table 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Table 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 7: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 9: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Table 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Table 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 12: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 14: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Table 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Table 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 17: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 19: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Table 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Table 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 22: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 24: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Table 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Table 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 27: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 29: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Table 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Table 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 32: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 34: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Table 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Table 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 37: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 38: Marketed Drugs
Table 39: Pipeline Drugs
Table 40:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 41:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 42:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 43: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 44: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 45: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 46: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 47: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 48: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 49: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 50: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 51: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 52: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 53: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 54: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 55: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 56: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 57: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 58: UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 59: UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 60: UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 61: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 62: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 63: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 4: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Table 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Table 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 7: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Table 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 9: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Table 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Table 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 12: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Table 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 14: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Table 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Table 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 17: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in France
Table 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 19: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Table 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Table 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 22: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Table 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 24: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Table 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Table 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 27: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Table 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 29: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Table 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Table 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 32: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Table 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 34: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Table 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Table 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 37: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Table 38: Marketed Drugs
Table 39: Pipeline Drugs
Table 40:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 41:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 42:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 43: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 44: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 45: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 46: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 47: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 48: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 49: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 50: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 51: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 52: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 53: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 54: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 55: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 56: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 57: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 58: UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 59: UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 60: UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 61: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Table 62: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Table 63: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
*Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 4: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Figure 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Figure 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 7: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 9: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Figure 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Figure 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 12: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 14: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Figure 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Figure 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 17: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 19: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Figure 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Figure 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 22: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 24: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Figure 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Figure 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 27: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 29: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Figure 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Figure 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 32: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 34: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Figure 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Figure 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 37: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 38: Marketed Drugs
Figure 39: Emerging Drugs
Figure 40:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 41:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 42:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 43: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 44: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 45: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 46: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 47: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 48: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 49: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 50: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 51: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 52: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 53: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 54: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 55: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 56: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 57: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 58: UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 59: UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 60: UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 61: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 62: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 63: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
*Indication Specific
Figure 1: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 4: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Figure 5: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in United States*
Figure 6: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 7: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in United States
Figure 8: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 9: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Figure 10: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Germany*
Figure 11: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 12: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Germany
Figure 13: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 14: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Figure 15: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in France*
Figure 16: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 17: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in France
Figure 18: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 19: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Figure 20: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Italy*
Figure 21: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 22: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Italy
Figure 23: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 24: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Figure 25: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Spain*
Figure 26: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 27: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Spain
Figure 28: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 29: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Figure 30: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in UK*
Figure 31: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 32: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in UK
Figure 33: Prevalent/Incident Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 34: Sub-Type Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Figure 35: Sex- Specific Cases of the Pulmonary Arterial Hypertension (PAH) in Japan*
Figure 36: Diagnosed Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 37: Treated Cases of the Pulmonary Arterial Hypertension (PAH) in Japan
Figure 38: Marketed Drugs
Figure 39: Emerging Drugs
Figure 40:7MM- Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 41:7MM- Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 42:7MM- Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 43: United States-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 44: United States-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 45: United States-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 46: Germany-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 47: Germany-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 48: Germany-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 49: France-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 50: France-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 51: France-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 52: Italy-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 53: Italy-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 54: Italy-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 55: Spain-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 56: Spain-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 57: Spain-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 58: UK-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 59: UK-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 60: UK-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 61: Japan-Market Size of Pulmonary Arterial Hypertension (PAH) in USD MM
Figure 62: Japan-Market Share Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
Figure 63: Japan-Market Sales of Pulmonary Arterial Hypertension (PAH) by Therapies in USD MM
*Indication Specific
